CDSCO Panel nod to AstraZeneca Olaparib for BRCA Mutated HER2 Negative Breast Cancer - Video
|
Overview
Based on the scientific data provided by the drug maker AstraZeneca, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod for the additional indication of the anticancer Drug Olaparib film coated tablet 100/150 mg for breast cancer with adult patients with BRCA-mutated HaeR2- negative.
This came after the firm-presented interim report of the ongoing Phase IV clinical trial of Olaparib Film Coated Tablet 100/150 mg as per the condition of the permission (IMP-ND-189/2018) granted to the firm.
For more details, check out the fulls story on the link below:
AstraZeneca Olaparib Gets CDSCO Panel Okay For BRCA Mutated HER2 Negative Breast Cancer
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
